Previous 10 | Next 10 |
2023-05-24 08:28:00 ET EpicQuest Education Group International ( EEIQ ) +92% . GigaCloud Technology ( GCT ) +37% Q1 earnings call release The Necessity Retail ( RTL ) +25% necessity retail rEIT to merge and internalize management. Smart for ...
2023-05-23 17:14:55 ET Gainers: Reata Pharmaceuticals ( RETA ) +10% . Urban Outfitters ( URBN ) +7% . COMPASS Pathways ( CMPS ) +6% . Stitch Fix ( SFIX ) +5% . TScan Therapeutics ( TCRX ) +4% . Losers: PTC The...
2023-05-23 09:42:04 ET Summary Despite recent production hitches with Skyclarys and the halt of bardoxolone, Reata Pharmaceuticals remains a compelling investment prospect. The expedited FDA review of Skyclarys' NDA supplement underscores the drug's crucial role in treating Friedr...
2023-05-17 12:13:55 ET Alzheimer's drug developer Prothena Corporation ( NASDAQ: PRTA ) announced Tuesday that Billy Dunn, who previously led the FDA's Office of Neuroscience, is joining the company's board of directors. The appointment comes less than three months after the FDA...
2023-05-11 00:04:08 ET Reata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Conference Call May 10, 2023 08:30 AM ET Company Participants Warren Huff - Chairman and Chief Executive Officer Dawn Bir - Executive Vice President and Chief Commercial Officer Andrea Loe...
2023-05-10 10:06:56 ET Reata Pharmaceuticals ( NASDAQ: RETA ) lost ~18% in the morning hours Wednesday despite reporting better than expected revenue for Q1 2023 as the biotech announced its plans to discontinue its studies for kidney disease candidate bardoxolone. The c...
2023-05-10 10:00:34 ET Gainers: CTI BioPharma ( CTIC ) +85% . Cano Health ( CANO ) +29% . TScan Therapeutics ( TCRX ) +24% . RxSight ( RXST ) +11% . Guardant Health ( GH ) +14% . Losers: Babylon Holdings ( BBLN ) -71...
2023-05-10 06:41:53 ET Reata Pharmaceuticals press release ( NASDAQ: RETA ): Q1 Non-GAAP EPS of -$1.81 in-line. Revenue of $0.2M (-78.0% Y/Y) beats by $0.04M . For further details see: Reata Pharmaceuticals Non-GAAP EPS of -$1.81 in-line, revenue of $0.2M bea...
SKYCLARYS ® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt Facility and Extended Cash Guidance Through th...
2023-05-09 11:40:53 ET Reata Pharmaceuticals ( NASDAQ: RETA ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$1.81 (-36.1% Y/Y) and the consensus Revenue Estimate is $0.16M (-82.4% Y/Y). Over the ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...